DelveInsight Publishes Report on Chemotherapy Induced Neuropathy Pipeline

DelveInsight has published its "Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight, 2026" report, offering a comprehensive overview of the CIPN treatment landscape.

The report analyzes the development pipeline of over 4 companies and 5 therapies. It covers drug candidates in both clinical and non-clinical stages, assessing them by product type, stage, route of administration, and molecule type. The analysis also identifies inactive pipeline products.

CIPN is a common and complex side effect of cancer treatment that can significantly impact patient quality of life. Despite improvements in cancer survival rates, CIPN remains a considerable challenge due to the lack of effective treatments. Symptoms such as pain, tingling, and numbness often persist for months after treatment and can interfere with daily activities.

The report highlights the need for a deeper understanding of CIPN's pathophysiology and the development of more effective prevention and treatment strategies. Current treatments, including therapies targeting ion channels and anti-inflammatory agents, offer some relief, but further research is essential.

DelveInsight's report aims to provide an in-depth analysis of the current state and future prospects of the CIPN pipeline, assisting industry stakeholders in understanding market trends and research challenges.